11.10.17
Quotient Clinical, a drug development services organization, has been renamed to Quotient Sciences. Following the acquisitions of Co-Formulate, QS Pharma and SeaView Research, this new identity better depicts the company’s global footprint and extended range of services.
Quotient is focused on providing a portfolio of services, including formulation development, clinical trial and commercial manufacturing, and clinical pharmacology. The company has 700 employees and five operating sites across the U.S. and the UK.
Quotient’s Translational Pharmaceutics platform integrates formulation development, real-time adaptive GMP manufacturing and clinical research, offering a new approach to outsourcing to contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs). Translational Pharmaceutics aims to accelerate development timelines and reduce overall costs.
“We are excited about the future of Quotient Sciences,” said Mark Egerton, chief executive officer, Quotient Sciences. “By integrating services typically found in disparate CDMOs and CROs, we break down barriers and support our customers to improve R&D productivity and accelerate the delivery of new medicines to patients around the world. We have a 30-year track record of service to a global customer base, including large multinational pharmaceutical companies to smaller virtual biotech organizations.”
Quotient Sciences will host an unveiling event at booth #1443 at AAPS, on Monday, Nov.13, 10:30 a.m.
Quotient is focused on providing a portfolio of services, including formulation development, clinical trial and commercial manufacturing, and clinical pharmacology. The company has 700 employees and five operating sites across the U.S. and the UK.
Quotient’s Translational Pharmaceutics platform integrates formulation development, real-time adaptive GMP manufacturing and clinical research, offering a new approach to outsourcing to contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs). Translational Pharmaceutics aims to accelerate development timelines and reduce overall costs.
“We are excited about the future of Quotient Sciences,” said Mark Egerton, chief executive officer, Quotient Sciences. “By integrating services typically found in disparate CDMOs and CROs, we break down barriers and support our customers to improve R&D productivity and accelerate the delivery of new medicines to patients around the world. We have a 30-year track record of service to a global customer base, including large multinational pharmaceutical companies to smaller virtual biotech organizations.”
Quotient Sciences will host an unveiling event at booth #1443 at AAPS, on Monday, Nov.13, 10:30 a.m.
